Trial ID 21473 | Maryland Oncology Hematology Trial ID 21473 – Maryland Oncology Hematology

Trial ID 21473

Trial Information - Phase III

ASTER: A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE

Protocol ID: ANT-007

Sponsor: Anthos Therapeutics

Status: PENDING OPEN

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Benign Hematology

Investigator

Juneja MD, Vinni

Status

PENDING OPEN

Sponsor

Anthos Therapeutics

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology